Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation
Advanced Science · 2026-05 · 13 (26)
DOI: 10.1002/advs.202521913 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 07.04.2026. Verfasst von David J Lundy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Translational Research, Biomedical. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 290 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, NSTC.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are currently defined. The field has expanded rapidly; however, translational progress is constrained by an incomplete mechanistic understanding, a lack of standardized measurements, and inconsistencies in regulatory classification. This review provides a critical synthesis of current EV research from an analytical and translational perspective, emphasizing the measurement science needed to define, compare, and benchmark EV preparations as therapeutic products. We discuss evolving regulatory frameworks and recent updates to the MISEV guidelines, highlighting the need for operational definitions grounded in source material, isolation method, and molecular markers. Updated workflow considerations are presented across EV production and characterization, with a focus on orthogonal analyses, quantification of co‐isolates, and potency assays that support reproducibility and quality control. Together, these advances and ongoing challenges underscore the need for analytical rigor to transform EV research from descriptive studies into a reproducible and quantitative measurement science.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University, New Taipei City, Taiwan.
- International PhD Program in Biomedical Engineering, Taipei Medical University, New Taipei City, Taiwan.
- David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
- Graduate School of Pure and Applied Sciences, University of Tsukuba, Tsukuba, Japan.
- Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan.
Förderung
- National Science and Technology Council
- NSTC
Zitieren
APA
Lundy, D. J., Chau, Z. L., Chen, S. Y., Fujisawa, N., Hill, J. J., Hsu, B. M., Liu, J. K., Mai, K. W., & Lai, J. J. (2026). Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation. Advanced Science, 13(26). https://doi.org/10.1002/advs.202521913
Vancouver
Lundy DJ, Chau ZL, Chen SY, Fujisawa N, Hill JJ, Hsu BM, et al. Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation. Advanced Science. 2026;13(26). doi:10.1002/advs.202521913
BibTeX
@article{Lundy2026,
author = {Lundy, David J and Chau, Zoe L and Chen, Sheng-You and Fujisawa, Nanami and Hill, John J and Hsu, Barnett M and Liu, Joanne K and Mai, Karol W and Lai, James J},
title = {Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {26},
doi = {10.1002/advs.202521913}
}
EUVIMED